Herceptin Adjuvant Breast Cancer Sales Slow In First Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech eyes additional opportunities for trastuzumab in adjuvant setting in node-positive, hormone receptor-positive breast cancer patients.